fda bpc-157 category 2 compounding 2023 FDA's own advisory committee voted 8-6 Thursday. BPC-157, on the list now, for ulcerative colitis. staff argued against it, laid out the data gaps, the whole case. Panel overruled them I am getting so many

I am getting so many messages there is a lot to review and a lot unfolding quickly! I want to take my time with the information and have been studying on rotations. Hopefully will get yall an only In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few FDA is reviewing seven peptides this week, BPC 157, MOTS c, and Epitalon among them. Committee meets Thursday and Friday, and the likely outcome is tighter restrictions on compounding pharmacies. Read past the headline This just in: The FDA is proposing to move 14 commonly used peptides from Category 2 to Category 1 on the compounding review list If finalized, this shift could significantly change

SKU: 57672377657 · From www.asociacionchamorro.org